Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-04-13 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于公司2017年股票期权激励计划首次授予股票期权第三个行权期及预留授予第二个行权期行权条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report regarding the achievement of exercise conditions for the third exercise period of the first grant and the second exercise period of the reserved grant under the 2017 stock option incentive plan of the company. It contains detailed explanations of the stock option plan, approval procedures, performance conditions, exercise quantities, prices, and the advisor's verification opinions. The document is lengthy (over 11,000 characters) and contains substantive financial and operational data related to the stock option incentive plan. It is not a simple announcement or certification but a detailed advisory report on the stock option plan's exercise conditions and approvals. This type of document fits best under the category of Audit Report / Information (AR), as it involves independent financial advisor's verification and opinions on the stock option incentive plan's compliance and exercise conditions, which is related to applied accounting and regulatory compliance information but is not a full annual or interim report. FY 2021
2021-04-13 Chinese
国浩律师（深圳）事务所关于公司2017年股票期权激励计划首次授予股票期权第三个行权期及预留授予第二个行权期可行权之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the exercise of stock options under a 2017 stock option incentive plan by a company. It details the legal compliance, approvals, conditions met for exercising stock options, and the impact on the company's shareholding structure. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to stock option exercises. It is not a proxy statement or voting result announcement, nor a board or management change announcement. It is a standalone legal opinion on a specific corporate action (stock option exercise). Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a compliance/legal document that does not fit other specific categories.
2021-04-13 Chinese
独立董事关于公司第四届董事会第十五次会议相关事项的独立意见
Governance Information Classification · 95% confidence The document is an independent directors' opinion on various company matters including stock option incentive plans and a bank credit application. It references compliance with regulatory guidelines and company internal rules, and provides independent opinions on the legitimacy and compliance of stock option exercises and credit applications. The document is not a financial report, earnings release, or audit report, but rather a formal opinion related to governance and compliance matters. It does not announce voting results or changes in management, nor is it a proxy or AGM material. The content aligns with governance-related disclosures, specifically independent directors' opinions on company governance and compliance with stock incentive plans and credit facilities. Therefore, the document best fits the category of Governance Information (CGR). The document length is 2688 characters, which is too short for a full report but sufficient for a governance opinion statement. No indication it is a report publication announcement or regulatory filing. Confidence is high due to clear governance focus and independent directors' opinions.
2021-04-13 Chinese
关于2016年限制性股票激励计划预留授予第三个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the achievement of conditions for the third release period of restricted stock under a 2016 stock incentive plan. It details the number of shares eligible for release, the performance conditions met, and the approval by the board and independent directors. The document is focused on stock incentive plan details, stock release conditions, and related approvals. It is not a financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting result announcement. The document is a formal announcement about the stock incentive plan's restricted stock release event, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share-based compensation events and related corporate actions, but not a full report or financial statement. The document length and detail confirm it is not a brief announcement but a full regulatory disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-13 Chinese
上海荣正投资咨询股份有限公司关于公司2019年股票期权激励计划第二个行权期行权条件成就之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report regarding the achievement of exercise conditions for the second exercise period of the 2019 stock option incentive plan of the company 健帆生物科技集团股份有限公司. It includes detailed explanations of the stock option plan, approval procedures, conditions for exercising options, number of exercisable options, and the advisor's verification opinion. The document is not a general annual report or earnings release but a specialized report related to stock option incentives and their conditions. It is not a simple announcement but a detailed advisory report with substantive content. This fits the category of Capital/Financing Update (CAP), as it relates to stock option plans and their exercise conditions, which affect the company's capital structure and financing arrangements.
2021-04-13 Chinese
关于2019年第二期股票期权激励计划第一个行权期可行权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the first exercise period of a 2019 stock option incentive plan. It details the number of stock options exercisable, the conditions met for exercising, the performance criteria, the legal and independent opinions, and the impact on the company's share structure. It is not a full financial report, earnings release, or management discussion, but rather a formal disclosure about stock option exercise rights and related corporate governance matters. This fits the category of Capital/Financing Update (CAP), as it relates to stock option plans and equity financing activities. The document length is sufficient and contains detailed information about the stock option exercise, not just a brief announcement or a certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2021-04-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.